Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) is one of 847 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Cardio Diagnostics to similar companies based on the strength of its risk, profitability, institutional ownership, valuation, analyst recommendations, earnings and dividends.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Cardio Diagnostics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Cardio Diagnostics Competitors | 9771 | 15002 | 45313 | 1578 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 95.87%. Given Cardio Diagnostics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Cardio Diagnostics has less favorable growth aspects than its rivals.
Risk & Volatility
Cardio Diagnostics has a beta of 2.29, meaning that its stock price is 129% more volatile than the S&P 500. Comparatively, Cardio Diagnostics’ rivals have a beta of 1.07, meaning that their average stock price is 7% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cardio Diagnostics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Cardio Diagnostics | $14,450.00 | -$6.50 million | -0.58 |
| Cardio Diagnostics Competitors | $695.89 million | $9.64 million | -10.01 |
Cardio Diagnostics’ rivals have higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Cardio Diagnostics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
| Cardio Diagnostics Competitors | -9,046.42% | -198.98% | -30.68% |
Summary
Cardio Diagnostics rivals beat Cardio Diagnostics on 10 of the 13 factors compared.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
